The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksUpdated×2•Originally published 21 April 2026•Updated 23 April 2026•

1 min read

ImmunityBio Faces Class Action Lawsuit Over Alleged Securities Fraud

Key Facts

1A securities fraud class action lawsuit has been filed against ImmunityBio for the period between January 19 and March 24, 2026.

2Allegations involve material misstatements or omissions concerning the company's lead biologic product, Anktiva.

about 1 month ago

Version History

Version 2about 1 month ago

What changed: Updated to include the FDA warning letter, the 21% stock price collapse, and the $2 billion loss in market capitalization.

Version 1about 1 month ago

What changed: A second law firm, Faruqi & Faruqi, LLP, has joined the legal action against the company and designated a specific partner as a contact for investors.

ImmunityBio, Inc. (IBRX) is facing intensified legal scrutiny following an FDA warning letter sent to its Executive Chairman regarding misleading efficacy claims for its biologic product, Anktiva. The news triggered a sharp 21% plunge in IBRX shares, wiping out approximately $2 billion in market capitalization. Consequently, a securities fraud class action has been filed for the period between January 19 and March 24, 2026, alleging material misstatements. Law firm Faruqi & Faruqi, LLP has joined the litigation, with partner James Wilson urging affected investors to discuss their legal rights. This follows initial actions by Kessler Topaz Meltzer & Check, with a court deadline of May 26, 2026, for investors to seek lead plaintiff status. These developments underscore significant concerns regarding corporate transparency and regulatory compliance within the biotech firm.